Capivasertib (AZD5363)

For research use only. Not for use in humans.

目录号:S8019

Capivasertib (AZD5363) Chemical Structure

CAS No. 1143532-39-1

Capivasertib (AZD5363)有效抑制Akt(Akt1/Akt2/3)的所有亚型,在无细胞试验中IC50为3 nM/8 nM/8 nM,对P70S6K/PKA也具有相似的抑制效果,而对ROCK1/2抑制活性较低。Phase 2。

规格 价格 库存 购买数量  
10mM (1mL in DMSO) RMB 1926.33 现货
RMB 1216.65 现货
RMB 3865.98 现货
RMB 9582.3 现货
有超大折扣

今日订购,明日送达,全国免运费!

全国免费电话:400-668-6834   |   Email:info@selleck.cn

客户使用Selleck生产的Capivasertib (AZD5363)发表文献85篇:

产品安全说明书

Akt抑制剂选择性比较

生物活性

产品描述 Capivasertib (AZD5363)有效抑制Akt(Akt1/Akt2/3)的所有亚型,在无细胞试验中IC50为3 nM/8 nM/8 nM,对P70S6K/PKA也具有相似的抑制效果,而对ROCK1/2抑制活性较低。Phase 2。
特性 AZD5363具有良好的临床前期耐受性,和AKT抑制剂的药效学特性,且不同于其他AKT抑制剂具有卓越的特性,已经进入临床开发阶段。[2]
靶点
Akt1 [1]
(Cell-free assay)
Akt2 [1]
(Cell-free assay)
Akt3 [1]
(Cell-free assay)
ROCK2 [1]
(Cell-free assay)
3 nM 8 nM 8 nM 56 nM
体外研究

AZD5363是有效的Akt抑制剂,抑制Akt1, Akt2 和 Akt3时,IC50分别为3 nM, 8 nM 和 8 nM。PIK3CA突变的激活,肿瘤抑制基因PTEN的丢失或失活,或HER2的扩增,都与AZD5363有着显著的关系。此外,还可以看出细胞系的RAS突变状态与抗AZD5363之间的相关性。[1]AZD5363在细胞中抑制AKT底物的磷酸化,效价约为0.3〜0.8μM。AZD5363抑制182种实体和血液肿瘤细胞系中的41种细胞增殖,效价为< 3 μM。[2]

Cell Data
Cell Lines Assay Type Concentration Incubation Time Formulation Activity Description PMID
PC-3  NHPKZmlHfW6ldHnvckBCe3OjeR?= NVfaPJc6OTBizszN NX\QSmpQOTJiaB?= MofHbY5lfWOnczDheZRweGijZ4m= M{iyV|xiKHSjcnfleF0oZ2KuYX7rK{BpemWoPTfoeJRxezpxL4D1Zo1m\C6wY3LpMo5tdS6waXiu[493NzJ|MkW4O|QxLz5{M{K1PFc1ODxxYU6=
LNCaP M4DaTGNmdGxiVnnhZoltcXS7IFHzd4F6 MYSwMVExODBibl2= M1K2fFAuPCCm Mon2doVlfWOnZDDMUmNiWCClZXzsJJZq[WKrbHn0fUBqdiCjIHTvd4UuKGGwZDD0bY1mNWSncHXu[IVvfCCvYX7u[ZLDqA>? NGrmXGo9[SC2YYLn[ZQ:L1:kbHHub{chcHKnZk2nbJR1eHN8Lz;weYJu\WRwbnPibU5vdG1wbnnoModwfi9{M{K1PFc1OCd-MkOyOVg4PDB:L3G+
DU145  NWfxWFNwTnWwY4Tpc44hSXO|YYm= NUXI[mZYOC53L{GvNVAh|ryP MYO0PEBp MmXP[I94dnKnZ4XsZZRmeyC2aHWgdIhwe3Cqb4L5cIF1cW:wIH;mJIRwf26|dILlZY0heGG2aIfhfUBxem:2ZXnud{BqdiCjIHTvd4Uu\GWyZX7k[Y51KG2jbn7ldi=> M3zOOVxiKHSjcnfleF0oZ2KuYX7rK{BpemWoPTfoeJRxezpxL4D1Zo1m\C6wY3LpMo5tdS6waXiu[493NzJ|MkW4O|QxLz5{M{K1PFc1ODxxYU6=
PC-3 MkTkSpVv[3Srb36gRZN{[Xl? NFXNU4gxNjVxMT:xNEDPxE1? M3T2bFQ5KGh? NFPhclNld3ewcnXneYxifGW|IITo[UBxcG:|cHjvdplt[XSrb36gc4Yh\G:5boP0doVidSCyYYToe4F6KHC{b4TlbY5{KGmwIHGg[I9{\S2mZYDlcoRmdnRibXHucoVz MYC8ZUB1[XKpZYS9K39jdGGwazegbJJm\j1paIT0dJM7Ny:ydXLt[YQvdmOkaT7ucI0vdmmqLnfvek8zOzJ3OEe0NEc,OjN{NUi3OFA9N2F-
C4-2  MmT0S5Jwf3SqIFnubIljcXSrb36gRZN{[Xl? MmrpNVAxNTVyMECgcm0> MYK3NkBp NV7G[ZNLcW6lcnXhd4V{KHSqZTDmdoFkfGmxbjDv[kBk\WyuczD1coRmemexaX7nJINmdGxiZHXheIg> MojMQIEhfGG{Z3X0QUdg[myjbnunJIhz\WZ;J3j0eJB{Qi9xcIXicYVlNm6lYnmucoxuNm6raD7nc5YwOjN7Nk[2NlEoRjJ|OU[2OlIyRC:jPh?=
LNCaP MUHHdo94fGhiSX7obYJqfGmxbjDBd5NigQ>? MVSxNFAuPTByMDDuUS=> NYrBbXBGPzJiaB?= NUfjWohCcW6lcnXhd4V{KHSqZTDmdoFkfGmxbjDv[kBk\WyuczD1coRmemexaX7nJINmdGxiZHXheIg> MmjYQIEhfGG{Z3X0QUdg[myjbnunJIhz\WZ;J3j0eJB{Qi9xcIXicYVlNm6lYnmucoxuNm6raD7nc5YwOjN7Nk[2NlEoRjJ|OU[2OlIyRC:jPh?=
C4-2  MUXHdo94fGhiSX7obYJqfGmxbjDBd5NigQ>? MoLDNU0yODByMDDuUS=> NHzQb5gxNTNiZB?= M3zMWolvcGmkaYTzJINmdGxidnnhZoltcXS7IHTvd4Uh\GWyZX7k[Y51dHl? Mkn3QIEhfGG{Z3X0QUdg[myjbnunJIhz\WZ;J3j0eJB{Qi9xcIXicYVlNm6lYnmucoxuNm6raD7nc5YwOjN7Nk[2NlEoRjJ|OU[2OlIyRC:jPh?=
LNCaP NY\GZoU1T3Kxd4ToJGlvcGmkaYTpc44hSXO|YYm= MWCxMVExODByIH7N MYiwMVMh\A>? NWfRS3RMcW6qaXLpeJMh[2WubDD2bYFjcWyrdImg[I9{\SCmZYDlcoRmdnSueR?= MmjoQIEhfGG{Z3X0QUdg[myjbnunJIhz\WZ;J3j0eJB{Qi9xcIXicYVlNm6lYnmucoxuNm6raD7nc5YwOjN7Nk[2NlEoRjJ|OU[2OlIyRC:jPh?=
C4-2  MVLGeY5kfGmxbjDBd5NigQ>? MojaOUDPxE1? M3P1eVAuOjRiaB?= NYLOdFZ3cW6qaXLpeJMheGixc4Doc5J6dGG2aX;uJI9nKHSqZTDkbZN1[WxiQVvUMZBifGi5YYmgZolwdWG{a3Xyd{BqdmOudXTpcochWFKDU{SwMEBmUUZ2RTygOGUuSlBzLDDtWG9TNCCjbnSgVFcxKFN4IHvpcoF{\SCrbjDhJJRqdWVvZHXw[Y5l\W62IH3hco5meg>? MU[8ZUB1[XKpZYS9K39jdGGwazegbJJm\j1paIT0dJM7Ny:ydXLt[YQvdmOkaT7ucI0vdmmqLnfvek8zOzl4Nk[yNUc,OjN7Nk[2NlE9N2F-
LNCaP MULGeY5kfGmxbjDBd5NigQ>? NEnNVIY2KM7:TR?= NHT5[VAxNTJ2IHi= Mn:zbY5pcWKrdIOgdIhwe3Cqb4L5cIF1cW:wIH;mJJRp\SCmaYP0ZYwhSUuWLYDheIh4[XliYnnvcYFzc2W{czDpcoNtfWSrbnegVHJCWzRyLDDlTWY1TSxiNFWtRnAyNCCvVF;SMEBidmRiUEewJHM3KGurbnHz[UBqdiCjIITpcYUu\GWyZX7k[Y51KG2jbn7ldi=> MoLOQIEhfGG{Z3X0QUdg[myjbnunJIhz\WZ;J3j0eJB{Qi9xcIXicYVlNm6lYnmucoxuNm6raD7nc5YwOjN7Nk[2NlEoRjJ|OU[2OlIyRC:jPh?=
C4-2  MYPGeY5kfGmxbjDBd5NigQ>? MWG1JO69VQ>? NV;PT4RzOC1{NDDo NGTtV5FqdmS3Y3XzJGFMXFN2N{OgZY5lKEGNVGSzNFgheGixc4Doc5J6dGG2aX;uJIlvKGFidHnt[UBl\XCnbnTlcpQhdWGwbnXy NFX0c3c9[SC2YYLn[ZQ:L1:kbHHub{chcHKnZk2nbJR1eHN8Lz;weYJu\WRwbnPibU5vdG1wbnnoModwfi9{M{m2OlYzOSd-MkO5OlY3OjF:L3G+
LNCaP MYDGeY5kfGmxbjDBd5NigQ>? NHPib4o2KM7:TR?= NVjZNFNqOC1{NDDo NXnZXI1rcW6mdXPld{BCU1SVNEezJIFv\CCDS2TUN|A5KHCqb4PwbI9zgWyjdHnvckBqdiCjIITpcYUh\GWyZX7k[Y51KG2jbn7ldi=> MXq8ZUB1[XKpZYS9K39jdGGwazegbJJm\j1paIT0dJM7Ny:ydXLt[YQvdmOkaT7ucI0vdmmqLnfvek8zOzl4Nk[yNUc,OjN7Nk[2NlE9N2F-
PAMC82 M4D1Smdzd3e2aDDJcohq[mm2aX;uJGF{e2G7 MUDJR|UxRTNyIN88US=> NFvUSos9[SC2YYLn[ZQ:L1:kbHHub{chcHKnZk2nbJR1eHN8Lz;weYJu\WRwbnPibU5vdG1wbnnoModwfi9{NEC4PFM5Oid-MkSwPFg{QDJ:L3G+
MKN74 M3\pe2dzd3e2aDDJcohq[mm2aX;uJGF{e2G7 NF3PUlJKSzVyPUOwJO69VQ>? MVi8ZUB1[XKpZYS9K39jdGGwazegbJJm\j1paIT0dJM7Ny:ydXLt[YQvdmOkaT7ucI0vdmmqLnfvek8zPDB6OEO4Nkc,OjRyOEizPFI9N2F-
GTL-16 MVTHdo94fGhiSX7obYJqfGmxbjDBd5NigQ>? MV7JR|UxRTNyIN88US=> MUK8ZUB1[XKpZYS9K39jdGGwazegbJJm\j1paIT0dJM7Ny:ydXLt[YQvdmOkaT7ucI0vdmmqLnfvek8zPDB6OEO4Nkc,OjRyOEizPFI9N2F-
SNU-5 MWTHdo94fGhiSX7obYJqfGmxbjDBd5NigQ>? M2DyOmlEPTB;M{Cg{txO NInpSHI9[SC2YYLn[ZQ:L1:kbHHub{chcHKnZk2nbJR1eHN8Lz;weYJu\WRwbnPibU5vdG1wbnnoModwfi9{NEC4PFM5Oid-MkSwPFg{QDJ:L3G+
NUGC-4 NIL4TZVIem:5dHigTY5pcWKrdHnvckBCe3OjeR?= NHSzTlJKSzVyPUOwJO69VQ>? Mly1QIEhfGG{Z3X0QUdg[myjbnunJIhz\WZ;J3j0eJB{Qi9xcIXicYVlNm6lYnmucoxuNm6raD7nc5YwOjRyOEizPFIoRjJ2MEi4N|gzRC:jPh?=
SNU-216 NEn4ZpRIem:5dHigTY5pcWKrdHnvckBCe3OjeR?= NWG4ZWRwUUN3ME2zNEDPxE1? MVK8ZUB1[XKpZYS9K39jdGGwazegbJJm\j1paIT0dJM7Ny:ydXLt[YQvdmOkaT7ucI0vdmmqLnfvek8zPDB6OEO4Nkc,OjRyOEizPFI9N2F-
AZ521 M1uyd2dzd3e2aDDJcohq[mm2aX;uJGF{e2G7 MVnJR|UxRTJ3LkS0PEDPxE1? MUS8ZUB1[XKpZYS9K39jdGGwazegbJJm\j1paIT0dJM7Ny:ydXLt[YQvdmOkaT7ucI0vdmmqLnfvek8zPDB6OEO4Nkc,OjRyOEizPFI9N2F-
NUGC-3 NWLXS2poT3Kxd4ToJGlvcGmkaYTpc44hSXO|YYm= NWH6eJZ7UUN3ME2yNU45PzNizszN NF;IbIQ9[SC2YYLn[ZQ:L1:kbHHub{chcHKnZk2nbJR1eHN8Lz;weYJu\WRwbnPibU5vdG1wbnnoModwfi9{NEC4PFM5Oid-MkSwPFg{QDJ:L3G+
OCUM-1 NH76OZVIem:5dHigTY5pcWKrdHnvckBCe3OjeR?= M1WzdGlEPTB;MUSuOVE2KM7:TR?= MWG8ZUB1[XKpZYS9K39jdGGwazegbJJm\j1paIT0dJM7Ny:ydXLt[YQvdmOkaT7ucI0vdmmqLnfvek8zPDB6OEO4Nkc,OjRyOEizPFI9N2F-
SNU-16 Mn\RS5Jwf3SqIFnubIljcXSrb36gRZN{[Xl? M3L5cmlEPTB;MUGuNFk4KM7:TR?= NUjk[2RYRGFidHHy[4V1RSehYnzhcosoKGi{ZX[9K4h1fHC|Oj:vdJVjdWWmLn7jZokvdmyvLn7pbE5od3ZxMkSwPFg{QDJpPkK0NFg5Ozh{PD;hQi=>
SNU-484 NUXZfYx3T3Kxd4ToJGlvcGmkaYTpc44hSXO|YYm= NXf6e3BiUUN3ME23MlM6OiEQvF2= MX[8ZUB1[XKpZYS9K39jdGGwazegbJJm\j1paIT0dJM7Ny:ydXLt[YQvdmOkaT7ucI0vdmmqLnfvek8zPDB6OEO4Nkc,OjRyOEizPFI9N2F-
KATO III NX;MUYY6T3Kxd4ToJGlvcGmkaYTpc44hSXO|YYm= MlXjTWM2OD15LkK2O{DPxE1? NVvxSVNXRGFidHHy[4V1RSehYnzhcosoKGi{ZX[9K4h1fHC|Oj:vdJVjdWWmLn7jZokvdmyvLn7pbE5od3ZxMkSwPFg{QDJpPkK0NFg5Ozh{PD;hQi=>
HS746T M4DsXGdzd3e2aDDJcohq[mm2aX;uJGF{e2G7 NGDtXWRKSzVyPU[uNFg1KM7:TR?= NIrqV|U9[SC2YYLn[ZQ:L1:kbHHub{chcHKnZk2nbJR1eHN8Lz;weYJu\WRwbnPibU5vdG1wbnnoModwfi9{NEC4PFM5Oid-MkSwPFg{QDJ:L3G+
SNU-668 NGHCRnVIem:5dHigTY5pcWKrdHnvckBCe3OjeR?= MknDTWM2OD14LkCwN{DPxE1? MoryQIEhfGG{Z3X0QUdg[myjbnunJIhz\WZ;J3j0eJB{Qi9xcIXicYVlNm6lYnmucoxuNm6raD7nc5YwOjRyOEizPFIoRjJ2MEi4N|gzRC:jPh?=
SNU-601 Ml\0S5Jwf3SqIFnubIljcXSrb36gRZN{[Xl? NEfWVFlKSzVyPUWuPVM5KM7:TR?= NXfQTms5RGFidHHy[4V1RSehYnzhcosoKGi{ZX[9K4h1fHC|Oj:vdJVjdWWmLn7jZokvdmyvLn7pbE5od3ZxMkSwPFg{QDJpPkK0NFg5Ozh{PD;hQi=>
SNU-1 NHrkepJIem:5dHigTY5pcWKrdHnvckBCe3OjeR?= Ml3PTWM2OD13LkK1PEDPxE1? NGDPbZI9[SC2YYLn[ZQ:L1:kbHHub{chcHKnZk2nbJR1eHN8Lz;weYJu\WRwbnPibU5vdG1wbnnoModwfi9{NEC4PFM5Oid-MkSwPFg{QDJ:L3G+
SNU-638 NILWZoZIem:5dHigTY5pcWKrdHnvckBCe3OjeR?= NYDW[YdSUUN3ME20MlUzOyEQvF2= M1:weFxiKHSjcnfleF0oZ2KuYX7rK{BpemWoPTfoeJRxezpxL4D1Zo1m\C6wY3LpMo5tdS6waXiu[493NzJ2MEi4N|gzLz5{NEC4PFM5OjxxYU6=
SNU-620 M4WzXWdzd3e2aDDJcohq[mm2aX;uJGF{e2G7 M2XRXmlEPTB;Mz6zPFQh|ryP NV;WXXQ6RGFidHHy[4V1RSehYnzhcosoKGi{ZX[9K4h1fHC|Oj:vdJVjdWWmLn7jZokvdmyvLn7pbE5od3ZxMkSwPFg{QDJpPkK0NFg5Ozh{PD;hQi=>
MKN1 NVu3cHJlT3Kxd4ToJGlvcGmkaYTpc44hSXO|YYm= NIfPdWdKSzVyPUKuOFIyKM7:TR?= MXO8ZUB1[XKpZYS9K39jdGGwazegbJJm\j1paIT0dJM7Ny:ydXLt[YQvdmOkaT7ucI0vdmmqLnfvek8zPDB6OEO4Nkc,OjRyOEizPFI9N2F-
23132/87 NHX1U4NIem:5dHigTY5pcWKrdHnvckBCe3OjeR?= NYrhdGt5UUN3ME2xMlY4OSEQvF2= NEjlcmE9[SC2YYLn[ZQ:L1:kbHHub{chcHKnZk2nbJR1eHN8Lz;weYJu\WRwbnPibU5vdG1wbnnoModwfi9{NEC4PFM5Oid-MkSwPFg{QDJ:L3G+
NCI-N87 NWGzT216T3Kxd4ToJGlvcGmkaYTpc44hSXO|YYm= NUDvWGRIUUN3ME2xMlA{PyEQvF2= MXO8ZUB1[XKpZYS9K39jdGGwazegbJJm\j1paIT0dJM7Ny:ydXLt[YQvdmOkaT7ucI0vdmmqLnfvek8zPDB6OEO4Nkc,OjRyOEizPFI9N2F-
AGS NYjle5J1T3Kxd4ToJGlvcGmkaYTpc44hSXO|YYm= NGDkXlNKSzVyPUCuOVUzKM7:TR?= MnSyQIEhfGG{Z3X0QUdg[myjbnunJIhz\WZ;J3j0eJB{Qi9xcIXicYVlNm6lYnmucoxuNm6raD7nc5YwOjRyOEizPFIoRjJ2MEi4N|gzRC:jPh?=
IM95m NVTNXplFT3Kxd4ToJGlvcGmkaYTpc44hSXO|YYm= MUnJR|UxRTBwNUGg{txO NYrqUFIzRGFidHHy[4V1RSehYnzhcosoKGi{ZX[9K4h1fHC|Oj:vdJVjdWWmLn7jZokvdmyvLn7pbE5od3ZxMkSwPFg{QDJpPkK0NFg5Ozh{PD;hQi=>
HGC27 NU\OcoZpT3Kxd4ToJGlvcGmkaYTpc44hSXO|YYm= M17IdWlEPTB;MD60OFUh|ryP NXnQUpB2RGFidHHy[4V1RSehYnzhcosoKGi{ZX[9K4h1fHC|Oj:vdJVjdWWmLn7jZokvdmyvLn7pbE5od3ZxMkSwPFg{QDJpPkK0NFg5Ozh{PD;hQi=>
PC-9 NF3RfXFHfW6ldHnvckBCe3OjeR?= MnjrNU82NzFyIN88US=> MljIOE8zPCCq NGHTe|JqdmO{ZXHz[ZMhSUuWIIDoc5NxcG:{eXzheIlwdg>? MUO8ZUB1[XKpZYS9K39jdGGwazegbJJm\j1paIT0dJM7Ny:ydXLt[YQvdmOkaT7ucI0vdmmqLnfvek8zPDl3N{[4Nkc,OjR7NUe2PFI9N2F-
NCI-H522 NFzQZ2RHfW6ldHnvckBCe3OjeR?= M2fDUlEwPS9zMDFOwG0> NUXKTopFPC9{NDDo M{HZSYlv[3KnYYPld{BCU1RicHjvd5Bpd3K7bHH0bY9v Mn20QIEhfGG{Z3X0QUdg[myjbnunJIhz\WZ;J3j0eJB{Qi9xcIXicYVlNm6lYnmucoxuNm6raD7nc5YwOjR7NUe2PFIoRjJ2OUW3OlgzRC:jPh?=
PC-9 M3HINWdzd3e2aDDJcohq[mm2aX;uJGF{e2G7 NXPwOG51UUN3ME25MlMhMMLzMT6yLUDPxE1? NEHOZ|A9[SC2YYLn[ZQ:L1:kbHHub{chcHKnZk2nbJR1eHN8Lz;weYJu\WRwbnPibU5vdG1wbnnoModwfi9{NEm1O|Y5Oid-MkS5OVc3QDJ:L3G+
NCI-H522 NW\hdVFCT3Kxd4ToJGlvcGmkaYTpc44hSXO|YYm= MonaTWM2OD1zMT6zJEjDuTJwNzmg{txO NWm0VZpoRGFidHHy[4V1RSehYnzhcosoKGi{ZX[9K4h1fHC|Oj:vdJVjdWWmLn7jZokvdmyvLn7pbE5od3ZxMkS5OVc3QDJpPkK0PVU4Pjh{PD;hQi=>
MR49F M1T5TWdzd3e2aDDJcohq[mm2aX;uJGF{e2G7 MV2wMVUh|ryP MorjOFghcA>? MnzFbY5pcWKrdIOgZ4VtdCCpcn;3eIghcW5iYTDkc5NmKGSncHXu[IVvfCCvYX7u[ZI> M{TISFxiKHSjcnfleF0oZ2KuYX7rK{BpemWoPTfoeJRxezpxL4D1Zo1m\C6wY3LpMo5tdS6waXiu[493NzJ3MUWxNFEzLz5{NUG1NVAyOjxxYU6=
MR49C M3yxXGdzd3e2aDDJcohq[mm2aX;uJGF{e2G7 Ml;4NE02KM7:TR?= MmrhOFghcA>? MUTpcohq[mm2czDj[YxtKGe{b4f0bEBqdiCjIHTvd4Uh\GWyZX7k[Y51KG2jbn7ldi=> NGXaW|g9[SC2YYLn[ZQ:L1:kbHHub{chcHKnZk2nbJR1eHN8Lz;weYJu\WRwbnPibU5vdG1wbnnoModwfi9{NUG1NVAyOid-MkWxOVExOTJ:L3G+
SKBR3 MmThS5Jwf3SqIFnubIljcXSrb36gRZN{[Xl? NUOzRohPOC1zLkO1JO69VQ>? NHi0[Vc2KGR? MYXlcohidmOnczD0bIUh\3Kxd4ToJIlvcGmkaYTpc44hd2ZiQWrEPFk{OQ>? NXvu[|JURGFidHHy[4V1RSehYnzhcosoKGi{ZX[9K4h1fHC|Oj:vdJVjdWWmLn7jZokvdmyvLn7pbE5od3ZxMk[wPVU1PzVpPkK2NFk2PDd3PD;hQi=>
KPL4 NYrSR2FUT3Kxd4ToJGlvcGmkaYTpc44hSXO|YYm= NV3UZXF[OC1zLkO1JO69VQ>? MWG1JIQ> MYrlcohidmOnczD0bIUh\3Kxd4ToJIlvcGmkaYTpc44hd2ZiQWrEPFk{OQ>? MnvyQIEhfGG{Z3X0QUdg[myjbnunJIhz\WZ;J3j0eJB{Qi9xcIXicYVlNm6lYnmucoxuNm6raD7nc5YwOjZyOUW0O|UoRjJ4MEm1OFc2RC:jPh?=
BT474c NWLBdXM{T3Kxd4ToJGlvcGmkaYTpc44hSXO|YYm= MVKwMVEvOzVizszN NGn6V482KGR? NYWzdmdC\W6qYX7j[ZMhfGinIHfyc5d1cCCrbnjpZol1cW:wIH;mJGFbTDh7M{G= MYe8ZUB1[XKpZYS9K39jdGGwazegbJJm\j1paIT0dJM7Ny:ydXLt[YQvdmOkaT7ucI0vdmmqLnfvek8zPjB7NUS3OUc,OjZyOUW0O|U9N2F-
HCC1954 NXK1cZozT3Kxd4ToJGlvcGmkaYTpc44hSXO|YYm= NFvxWWUxNTFwM{Wg{txO MXi1JIQ> NUL1d4Rv\W6qYX7j[ZMhfGinIHfyc5d1cCCrbnjpZol1cW:wIH;mJGFbTDh7M{G= NX61S2tiRGFidHHy[4V1RSehYnzhcosoKGi{ZX[9K4h1fHC|Oj:vdJVjdWWmLn7jZokvdmyvLn7pbE5od3ZxMk[wPVU1PzVpPkK2NFk2PDd3PD;hQi=>
TamR MYjHdo94fGhiSX7obYJqfGmxbjDBd5NigQ>? NFT6XJQ1ODBibl2= NVnyRow6PiCm M2H3dYlv[3KnYYPl[EBlenWpIIPlcpNqfGm4aYT5JI9nKDRvT1jUJIFv\CCodXz2[ZN1emGwdB?= M{K4eFxiKHSjcnfleF0oZ2KuYX7rK{BpemWoPTfoeJRxezpxL4D1Zo1m\C6wY3LpMo5tdS6waXiu[493NzJ4M{WxN|I{Lz5{NkO1NVMzOzxxYU6=
T74D LTED NXrHUWgyT3Kxd4ToJGlvcGmkaYTpc44hSXO|YYm= MkPPNVAxKG6P MUm2JIQ> MofmbY5kemWjc3XkJIRzfWdic3Xud4l1cX[rdImgc4YhPC2RSGSgZY5lKG[3bI\ld5Rz[W62 MXK8ZUB1[XKpZYS9K39jdGGwazegbJJm\j1paIT0dJM7Ny:ydXLt[YQvdmOkaT7ucI0vdmmqLnfvek8zPjN3MUOyN{c,OjZ|NUGzNlM9N2F-
ZR75 LTED NYrsXYNPT3Kxd4ToJGlvcGmkaYTpc44hSXO|YYm= NEHURXcyODBibl2= NV7jWYY2PiCm NHv3N|dqdmO{ZXHz[YQh\HK3ZzDz[Y5{cXSrdnn0fUBw\iB2LV;IWEBidmRiZoXseoV{fHKjboS= NXLDZoVHRGFidHHy[4V1RSehYnzhcosoKGi{ZX[9K4h1fHC|Oj:vdJVjdWWmLn7jZokvdmyvLn7pbE5od3ZxMk[zOVE{OjNpPkK2N|UyOzJ|PD;hQi=>
MCF7 LTED MVPHdo94fGhiSX7obYJqfGmxbjDBd5NigQ>? NV\BS3RvOjByIH7N NGnrTHM3KGR? NIHhd4xqdmO{ZXHz[YQh\HK3ZzDz[Y5{cXSrdnn0fUBw\iB2LV;IWEBidmRiZoXseoV{fHKjboS= MXe8ZUB1[XKpZYS9K39jdGGwazegbJJm\j1paIT0dJM7Ny:ydXLt[YQvdmOkaT7ucI0vdmmqLnfvek8zPjN3MUOyN{c,OjZ|NUGzNlM9N2F-
1%MCF7 M2mxVWdzd3e2aDDJcohq[mm2aX;uJGF{e2G7 NXjydYFVPDByIH7N MmLmOkBl MW\pcoNz\WG|ZXSg[JJ2\yC|ZX7zbZRqfmm2eTDv[kA1NU:KVDDhcoQh\nWudnXzeJJidnR? MmfOQIEhfGG{Z3X0QUdg[myjbnunJIhz\WZ;J3j0eJB{Qi9xcIXicYVlNm6lYnmucoxuNm6raD7nc5YwOjZ|NUGzNlMoRjJ4M{WxN|I{RC:jPh?=
T74D NYq4d4NUT3Kxd4ToJGlvcGmkaYTpc44hSXO|YYm= M37veFExOCCwTR?= M3:yNFYh\A>? NFyxVnhqdmO{ZXHz[YQh\HK3ZzDz[Y5{cXSrdnn0fUBw\iB2LV;IWEBidmRiZoXseoV{fHKjboS= M2nWb|xiKHSjcnfleF0oZ2KuYX7rK{BpemWoPTfoeJRxezpxL4D1Zo1m\C6wY3LpMo5tdS6waXiu[493NzJ4M{WxN|I{Lz5{NkO1NVMzOzxxYU6=
ZR75 NVKwWFJpT3Kxd4ToJGlvcGmkaYTpc44hSXO|YYm= MVmxNFAhdk1? NE[5T2M3KGR? MUjpcoNz\WG|ZXSg[JJ2\yC|ZX7zbZRqfmm2eTDv[kA1NU:KVDDhcoQh\nWudnXzeJJidnR? Mkf6QIEhfGG{Z3X0QUdg[myjbnunJIhz\WZ;J3j0eJB{Qi9xcIXicYVlNm6lYnmucoxuNm6raD7nc5YwOjZ|NUGzNlMoRjJ4M{WxN|I{RC:jPh?=
MCF7 NFvBPI9Iem:5dHigTY5pcWKrdHnvckBCe3OjeR?= NXja[FF1OjByIH7N M2D5Z|Yh\A>? MlzubY5kemWjc3XkJIRzfWdic3Xud4l1cX[rdImgc4YhPC2RSGSgZY5lKG[3bI\ld5Rz[W62 M13qNVxiKHSjcnfleF0oZ2KuYX7rK{BpemWoPTfoeJRxezpxL4D1Zo1m\C6wY3LpMo5tdS6waXiu[493NzJ4M{WxN|I{Lz5{NkO1NVMzOzxxYU6=
LNCaP M3nmXGZ2dmO2aX;uJIF{e2G7 NGXrS4hKdmirYnn0bY9vKG:oIFHreEBqdiCSVFXOMYRm\mmlaXXueEBpfW2jbjDMUmNiWCClZXzsd{Bie3Onc4Pl[EBieyCyaH;zdIhwenmuYYTpc44hd2ZiR2PLN4JmfGFuIFnDOVAhRSByLkC2JO69VS5? NWLBcIV4RGFidHHy[4V1RSehYnzhcosoKGi{ZX[9K4h1fHC|Oj:vdJVjdWWmLn7jZokvdmyvLn7pbE5od3ZxMkOzPVQzOThpPkKzN|k1OjF6PD;hQi=>
MDA-MB-468 NHnCS3hHfW6ldHnvckBie3OjeR?= NWPPempsOiCqcoO= M1nzc2lvcGmkaYTpc44hd2ZiQXv0JIlvKGi3bXHuJG1FSS2PQj20Olgh[2WubIOgZZN{\XO|ZXSgZZMhcW6qaXLpeIlwdiCxZjDHV2s{[mW2YTDwbI9{eGixconsZZRqd25iYX\0[ZIhOiCqcoOgZpkhdGG|ZYKgd4Nidm6rbnegZ5l1d22ndIL5MEBKSzVyIE2gNE4xQDlizszNMi=> M4ryW|xiKHSjcnfleF0oZ2KuYX7rK{BpemWoPTfoeJRxezpxL4D1Zo1m\C6wY3LpMo5tdS6waXiu[493NzJ|M{m0NlE5Lz5{M{O5OFIyQDxxYU6=
LNCaP M4fxbWZ2dmO2aX;uJIF{e2G7 M2rHRWlvcGmkaYTpc44hd2ZiQXv0JIlvKFCWRV6t[IVncWOrZX70JIh2dWGwIFzOR4FRKGOnbHzzJIF{e2W|c3XkJIF{KHCqb4PwbI9zgWyjdHnvckBw\iCSUlHTOFAtKEmFNUCgQUAxNjJ{IN88UU4> NWPTXlRoRGFidHHy[4V1RSehYnzhcosoKGi{ZX[9K4h1fHC|Oj:vdJVjdWWmLn7jZokvdmyvLn7pbE5od3ZxMkOzPVQzOThpPkKzN|k1OjF6PD;hQi=>
BT474c MljrSpVv[3Srb36gZZN{[Xl? MVPJcohq[mm2aX;uJI9nKEGtdDDpckBpfW2jbjDCWFQ4PGNiY3XscJMhcGG{Yn;ybY5oKEiHUkKrM3BKUzOFQTDkc5VjdGVibYX0ZY51KGG|c3Xzd4VlKGG|IIDoc5NxcG:{eXzheIlwdiCxZjDQVmFUPDBuIFnDOVAhRSByLkOxJO69VS5? MmPIQIEhfGG{Z3X0QUdg[myjbnunJIhz\WZ;J3j0eJB{Qi9xcIXicYVlNm6lYnmucoxuNm6raD7nc5YwOjN|OUSyNVgoRjJ|M{m0NlE5RC:jPh?=
MDA-MB-468 NXrxbJNZTnWwY4Tpc44h[XO|YYm= MXrJcohq[mm2aX;uJI9nKEGtdDDpckBRXEWQLXTl[olkcWWwdDDoeY1idiCPRFGtUWIuPDZ6IHPlcIx{KGG|c3Xzd4VlKGG|IIDoc5NxcG:{eXzheIlwdiCxZjDHV2s{[mW2YTygTWM2OCB;IECuN|gh|ryPLh?= NEXJRVE9[SC2YYLn[ZQ:L1:kbHHub{chcHKnZk2nbJR1eHN8Lz;weYJu\WRwbnPibU5vdG1wbnnoModwfi9{M{O5OFIyQCd-MkOzPVQzOTh:L3G+
MDA-MB-468 NY\uWYNqTnWwY4Tpc44h[XO|YYm= MoXTTY5pcWKrdHnvckBw\iCDa4SgbY4hWFSHTj3k[YZq[2mnboSgbJVu[W5iTVTBMW1DNTR4ODDj[YxteyCjc4Pld5Nm\CCjczDwbI9{eGixconsZZRqd25ib3[gVHJCWzRyLDDJR|UxKD1iMD6zPUDPxE1w NGjuUXY9[SC2YYLn[ZQ:L1:kbHHub{chcHKnZk2nbJR1eHN8Lz;weYJu\WRwbnPibU5vdG1wbnnoModwfi9{M{O5OFIyQCd-MkOzPVQzOTh:L3G+
BT474c MkXJSpVv[3Srb36gZZN{[Xl? M331OmlvcGmkaYTpc44hd2ZiQXv0JIlvKGi3bXHuJGJVPDd2YzDj[YxteyCqYYLic5JqdmdiSFXSNkswWEmNM1PBJIRwfWKuZTDteZRidnRiYYPz[ZN{\WRiYYOgdIhwe3Cqb4L5cIF1cW:wIH;mJGdUUzOkZYThMEBKSzVyIE2gNE44PiEQvF2u NX31e2pKRGFidHHy[4V1RSehYnzhcosoKGi{ZX[9K4h1fHC|Oj:vdJVjdWWmLn7jZokvdmyvLn7pbE5od3ZxMkOzPVQzOThpPkKzN|k1OjF6PD;hQi=>
RT4 MonWSpVv[3Srb36gZZN{[Xl? M1HxbmlvcGmkaYTpc44hd2ZiUFvBJIlvKFSVQ{Gg[IVncWOrZX70JIh2dWGwIGLUOEBk\WyuczDhd5Nme3OnZDDhd{BUPiCyaH;zdIhwenmuYYTpc44tKEmFNUCgQUAyKM7:TT6= MXK8ZUB1[XKpZYS9K39jdGGwazegbJJm\j1paIT0dJM7Ny:ydXLt[YQvdmOkaT7ucI0vdmmqLnfvek8zOzN7NEKxPEc,OjN|OUSyNVg9N2F-
RT4 NWfmN2lZTnWwY4Tpc44h[XO|YYm= NGPGUm1KdmirYnn0bY9vKG:oIGC3NHM3UyCrbjDUV2MyKGSnZnnjbYVvfCCqdX3hckBTXDRiY3XscJMh[XO|ZYPz[YQh[XNiU{[gdIhwe3Cqb4L5cIF1cW:wLDDJR|UxKD1iNTFOwG0v NFmySFQ9[SC2YYLn[ZQ:L1:kbHHub{chcHKnZk2nbJR1eHN8Lz;weYJu\WRwbnPibU5vdG1wbnnoModwfi9{M{O5OFIyQCd-MkOzPVQzOTh:L3G+
PTEN-null LNCAP NX3FNZVsTnWwY4Tpc44h[XO|YYm= NWXWXVdrOSCqch?= MnfHTY5pcWKrdHnvckBw\iCDa4SgbY4hcHWvYX6gVHRGVi2wdXzsJGxPS0GSIHPlcIx{KGG|c3Xzd4VlKGG|IIP1dJBz\XO|aX;uJIlvKFCUQWO0NEBxcG:|cHjvdplt[XSrb36gZYZ1\XJiMTDodkBjgSCHTFnTRUBidmGueYPpd{whUUN3MDC9JFAvOzN4ODFOwG0v MYe8ZUB1[XKpZYS9K39jdGGwazegbJJm\j1paIT0dJM7Ny:ydXLt[YQvdmOkaT7ucI0vdmmqLnfvek8zPzB6OUKxNUc,OjdyOEmyNVE9N2F-
HCT116 M2PFbmFvfGmycn;sbYZmemG2aY\lJIF{e2G7 NWHhcmxtPzJiaILz MULBcpRqeHKxbHnm[ZJifGm4ZTDhZ5Rqfmm2eTDh[4FqdnO2IHj1cYFvKEiFVEGxOkBk\WyuczDh[pRmeiB5MjDodpMh[nliU2LCJIF{e2G7LDDJR|UxKD1iNT6yJO69VS5? NWjzS4tnRGFidHHy[4V1RSehYnzhcosoKGi{ZX[9K4h1fHC|Oj:vdJVjdWWmLn7jZokvdmyvLn7pbE5od3ZxMkewPFkzOTFpPkK3NFg6OjFzPD;hQi=>
OVCAR8 MYXBcpRqeHKxbHnm[ZJifGm4ZTDhd5NigQ>? NYLtTVRuPzJiaILz NHXJfplCdnSrcILvcIln\XKjdHn2[UBi[3Srdnn0fUBi\2GrboP0JIh2dWGwIF;WR2FTQCClZXzsd{Bi\nSncjC3NkBpenNiYomgV3JDKGG|c3H5MEBKSzVyIE2gO{4zPyEQvF2u NFS4d2Y9[SC2YYLn[ZQ:L1:kbHHub{chcHKnZk2nbJR1eHN8Lz;weYJu\WRwbnPibU5vdG1wbnnoModwfi9{N{C4PVIyOSd-MkewPFkzOTF:L3G+
A673 NXPJVVBDeUiWUzDhd5NigQ>? NI\EUlVyUFSVIH;mJJBm\GmjdILpZ{Bk[W6lZYKgZ4VtdCCuaX7ld{B1dyCrZHXueIlngSCvdXz0bZBt\SCxcIDvdpR2dmm2aXXzJIZweiCmcoXnJJJmeHW{cH;zbY5oQiCScnntZZJ6KHOlcnXlckBnd3JiQU[3N{Bk\Wyucx?= M2i1ZlxiKHSjcnfleF0oZ2KuYX7rK{BpemWoPTfoeJRxezpxL4D1Zo1m\C6wY3LpMo5tdS6waXiu[493NzJ7NEO1NVM6Lz5{OUSzOVE{QTxxYU6=
DAOY Mlr6dWhVWyCjc4PhfS=> MUnxTHRUKG:oIIDl[IlifHKrYzDjZY5k\XJiY3XscEBtcW6nczD0c{Bq\GWwdHnmfUBufWy2aYDs[UBweHCxcoT1col1cWW|IH\vdkBlenWpIILldJVzeG:|aX7nPkBRemmvYYL5JJNkemWnbjDmc5IhTEGRWTDj[Yxtew>? NH7kWpU9[SC2YYLn[ZQ:L1:kbHHub{chcHKnZk2nbJR1eHN8Lz;weYJu\WRwbnPibU5vdG1wbnnoModwfi9{OUSzOVE{QSd-Mkm0N|UyOzl:L3G+
Saos-2 MUDxTHRUKGG|c3H5 M1HCUpFJXFNib3[gdIVlcWG2cnnjJINidmOncjDj[YxtKGyrbnXzJJRwKGmmZX70bYZ6KG23bITpdIxmKG:ycH;yeJVvcXSrZYOg[o9zKGS{dXegdoVxfXKyb4Ppcoc7KFC{aX3hdpkhe2O{ZXXuJIZweiCVYX;zMVIh[2WubIO= MkezQIEhfGG{Z3X0QUdg[myjbnunJIhz\WZ;J3j0eJB{Qi9xcIXicYVlNm6lYnmucoxuNm6raD7nc5YwOjl2M{WxN|koRjJ7NEO1NVM6RC:jPh?=
SK-N-SH NYKzephweUiWUzDhd5NigQ>? Mn3KdWhVWyCxZjDw[YRq[XS{aXOgZ4Fv[2W{IHPlcIwhdGmwZYOgeI8hcWSnboTp[pkhdXWudHnwcIUhd3Cyb4L0eY5qfGmnczDmc5Ih\HK3ZzDy[ZB2enCxc3nu[|ohWHKrbXHyfUB{[3KnZX6g[o9zKFONLV6tV2gh[2WubIO= NUfz[2NERGFidHHy[4V1RSehYnzhcosoKGi{ZX[9K4h1fHC|Oj:vdJVjdWWmLn7jZokvdmyvLn7pbE5od3ZxMkm0N|UyOzlpPkK5OFM2OTN7PD;hQi=>
NB1643 NEPLb3ZyUFSVIHHzd4F6 NEDR[HlyUFSVIH;mJJBm\GmjdILpZ{Bk[W6lZYKgZ4VtdCCuaX7ld{B1dyCrZHXueIlngSCvdXz0bZBt\SCxcIDvdpR2dmm2aXXzJIZweiCmcoXnJJJmeHW{cH;zbY5oQiCScnntZZJ6KHOlcnXlckBnd3JiTlKxOlQ{KGOnbHzz NYTRVFNvRGFidHHy[4V1RSehYnzhcosoKGi{ZX[9K4h1fHC|Oj:vdJVjdWWmLn7jZokvdmyvLn7pbE5od3ZxMkm0N|UyOzlpPkK5OFM2OTN7PD;hQi=>
MG 63 (6-TG R) MnPkdWhVWyCjc4PhfS=> MkHLdWhVWyCxZjDw[YRq[XS{aXOgZ4Fv[2W{IHPlcIwhdGmwZYOgeI8hcWSnboTp[pkhdXWudHnwcIUhd3Cyb4L0eY5qfGmnczDmc5Ih\HK3ZzDy[ZB2enCxc3nu[|ohWHKrbXHyfUB{[3KnZX6g[o9zKE2JIE[zJEg3NVSJIGKpJINmdGy| M4nJWFxiKHSjcnfleF0oZ2KuYX7rK{BpemWoPTfoeJRxezpxL4D1Zo1m\C6wY3LpMo5tdS6waXiu[493NzJ7NEO1NVM6Lz5{OUSzOVE{QTxxYU6=
Rh41 NYLkVZpmeUiWUzDhd5NigQ>? MkDxdWhVWyCxZjDw[YRq[XS{aXOgZ4Fv[2W{IHPlcIwhdGmwZYOgeI8hcWSnboTp[pkhdXWudHnwcIUhd3Cyb4L0eY5qfGmnczDmc5Ih\HK3ZzDy[ZB2enCxc3nu[|ohWHKrbXHyfUB{[3KnZX6g[o9zKFKqNEGgZ4VtdHN? NVryRnN3RGFidHHy[4V1RSehYnzhcosoKGi{ZX[9K4h1fHC|Oj:vdJVjdWWmLn7jZokvdmyvLn7pbE5od3ZxMkm0N|UyOzlpPkK5OFM2OTN7PD;hQi=>
SK-N-MC MkjmdWhVWyCjc4PhfS=> M2PvWJFJXFNib3[gdIVlcWG2cnnjJINidmOncjDj[YxtKGyrbnXzJJRwKGmmZX70bYZ6KG23bITpdIxmKG:ycH;yeJVvcXSrZYOg[o9zKGS{dXegdoVxfXKyb4Ppcoc7KFC{aX3hdpkhe2O{ZXXuJIZweiCVSz3OMW1EKGOnbHzz NH;rN5k9[SC2YYLn[ZQ:L1:kbHHub{chcHKnZk2nbJR1eHN8Lz;weYJu\WRwbnPibU5vdG1wbnnoModwfi9{OUSzOVE{QSd-Mkm0N|UyOzl:L3G+
NB-EBc1 MYTxTHRUKGG|c3H5 MUnxTHRUKG:oIIDl[IlifHKrYzDjZY5k\XJiY3XscEBtcW6nczD0c{Bq\GWwdHnmfUBufWy2aYDs[UBweHCxcoT1col1cWW|IH\vdkBlenWpIILldJVzeG:|aX7nPkBRemmvYYL5JJNkemWnbjDmc5IhVkJvRVLjNUBk\Wyucx?= NEjlTZE9[SC2YYLn[ZQ:L1:kbHHub{chcHKnZk2nbJR1eHN8Lz;weYJu\WRwbnPibU5vdG1wbnnoModwfi9{OUSzOVE{QSd-Mkm0N|UyOzl:L3G+
LAN-5 M{nI[JFJXFNiYYPzZZk> MkL1dWhVWyCxZjDw[YRq[XS{aXOgZ4Fv[2W{IHPlcIwhdGmwZYOgeI8hcWSnboTp[pkhdXWudHnwcIUhd3Cyb4L0eY5qfGmnczDmc5Ih\HK3ZzDy[ZB2enCxc3nu[|ohWHKrbXHyfUB{[3KnZX6g[o9zKEyDTj21JINmdGy| M4HmclxiKHSjcnfleF0oZ2KuYX7rK{BpemWoPTfoeJRxezpxL4D1Zo1m\C6wY3LpMo5tdS6waXiu[493NzJ7NEO1NVM6Lz5{OUSzOVE{QTxxYU6=
Rh18 MVnxTHRUKGG|c3H5 Mmj1dWhVWyCxZjDw[YRq[XS{aXOgZ4Fv[2W{IHPlcIwhdGmwZYOgeI8hcWSnboTp[pkhdXWudHnwcIUhd3Cyb4L0eY5qfGmnczDmc5Ih\HK3ZzDy[ZB2enCxc3nu[|ohWHKrbXHyfUB{[3KnZX6g[o9zKFKqMUigZ4VtdHN? NELiWlE9[SC2YYLn[ZQ:L1:kbHHub{chcHKnZk2nbJR1eHN8Lz;weYJu\WRwbnPibU5vdG1wbnnoModwfi9{OUSzOVE{QSd-Mkm0N|UyOzl:L3G+

... Click to View More Cell Line Experimental Data

Assay
Methods Test Index PMID
Western blot
pAKT / AKT / pGSK3β / GSK3β; 

PubMed: 26998062     


AZD5363 inhibited the phosphorylation of GSK3β, but increased the phosphorylation of AKT in a time-dependent manner in the (A) Hep-G2 cells. 

HER3 / pHER3 / HER2 / pHER2 / pPRAS40 / pS6 / p-4EBP1 / pFOXO / pERK / PARP / Cleaved PARP; 

PubMed: 26095475     


(A) BT474c or HCC1954 cells were treated for 24 h with increasing concentrations of AZD5363 ±0.3 μM or 1 μM AZD8931, respectively. Protein lysates were analysed by immunoblot with the indicated antibodies. Blots are representative of blots from 2–3 separate experiments. 

26998062 26095475
Immunofluorescence
p-Chk2 / γ-H2AX; 

PubMed: 29879757     


(C) Cells were treated with AZD1208 and AZD5363 alone or in combination for 5 days, and immunofluorescence analysis was subsequently performed. Confocal microscopy was used to observe the signals corresponding to p-Chk2 (red) and γ-H2AX (green). DAPI (blue) was used as a nuclear counterstain. CI, combination index. Scale bars=5 μm.

29879757
Growth inhibition assay
Cell viability; 

PubMed: 29879757     


Cells were seeded and cultured with increasing concentrations of AZD5363 and 1 μM AZD1208 every 3 days. The cells were cultured for 14 days until colonies formed and were then stained. The percentages of surviving cells were calculated by counting the number of colonies and are presented in a bar graph with standard error bars (n=3). a)p < 0.005. 

29879757
体内研究 AZD5363按100, 300 mg/kg剂量口服给药裸鼠,降低BT474c移植瘤中PRAS40, GSK3β,和 S6的磷酸化,这种作用具有剂量和时间依赖性,也可逆性地增加血糖浓度,且降低U87-MG移植瘤中2[18F]氟-2-脱氧-d-葡萄糖(18F-FDG)的摄取,这种作用存在剂量依赖性。AZD5363按130, 200, 和300 mg/kg剂量慢性口服给药从各种肿瘤类型衍生的移植瘤,包括抗Trastuzumab的HER2+乳腺癌模型,抑制移植瘤的生长,这种作用存在剂量依赖性。AZD5363在乳腺癌移植瘤中也显著增强 Docetaxel, Lapatinib, 和 Trastuzumab的抗肿瘤活性。[2]

推荐的实验操作(此推荐来自于公开的文献所以Selleck并不保证其有效性)

激酶实验:[1]
- 合并

Caliper Off-Chip Incubation迁移率变动分析:

通过 Caliper Off-Chip Incubation迁移率变动分析测评AZD5363和其他化合物抑制AKT1, AKT2, 和 AKT3活性的能力。活跃的重组AKT1,AKT2,或AKT3与5-FAM标记的定制合成的肽底物,及浓度不断增加的抑制剂温育。最终反应包含1 到 3 nM AKT1, AKT2, 或AKT3 酶; 1.5 mM 肽底物; AKT亚型的ATP为Km; 10 mM MgCl2, 4 mM DTT, 100 mM HEPES, 及0.015% Brij-35。反应在室温下温育1小时,然后加入含100 mM HEPES, 0.015% Brij-35 溶液, 0.1% 涂层试剂, 40 mM EDTA, 和5% DMSO的buffer终止反应。使用Caliper LC3000分析实验板,进行肽底物的分离,对磷酸化的产物进行电泳和激光诱导荧光的检测和量化。
细胞实验: [2]
- 合并
  • Cell lines: 182种实体和血液肿瘤细胞系
  • Concentrations: 0.003 μM-30 μM
  • Incubation Time: 72 小时
  • Method: 通过MTS和Sytox Green2种方法测定细胞增殖实验。细胞接种在96孔板中,在37°C下,含 5% CO2的环境中温育过夜。使用浓度为30 到 0.003μM的 AZD5363处理细胞72小时。对于MTS端点,通过CellTiter AQueous非放射性细胞增殖检测试剂测量细胞增殖。对于Sytox Green 端点,在TBS-EDTA buffer 中稀释的Sytox Green核酸染料加到细胞中(终浓度为0.13μM),使用Acumen Explorer测定死亡细胞数。通过加入Saponin(终浓度0.03%,在TBS-EDTA buffer中稀释)使细胞具有渗透性,温育过夜,并测量总细胞数。MTS 和Sytox Green 端点都是给药前测量,使用吸光度读数(MTS)或活细胞计数测定将实验组细胞的生长降低到未处理组细胞的一半所需要的浓度值。
    (Only for Reference)
动物实验:[2]
- 合并
  • Animal Models: 携带 BT474c, U87MG, KPL-4, HCC-1187 移植瘤的雌性裸鼠和雄性SCID小鼠
  • Dosages: 130 mg/Kg-300 mg/Kg
  • Administration: 口服处理
    (Only for Reference)

溶解度 (25°C)

体外 DMSO 86 mg/mL (200.5 mM)
Water Insoluble
Ethanol Insoluble

* 溶解度检测是由Selleck技术部门检测的,可能会和文献中提供的溶解度有所差异,这是由于生产工艺和批次不同产生的正常现象。请按照顺序依次加入各个纯溶剂。

化学数据

分子量 428.92
化学式

C21H25ClN6O2

CAS号 1143532-39-1
储存条件 粉状
溶于溶剂
别名 N/A

动物体内配方计算器 (澄清溶液)

第一步:请输入基本实验信息(考虑到实验过程中的损耗,建议多配一只动物的药量)
给药剂量 mg/kg 动物平均体重 g 每只动物给药体积 ul 动物数量
第二步:请输入动物体内配方组成(配方适用于不溶于水的药物;不同批次药物配方比例不同,请联系Selleck为您提供正确的澄清溶液配方)
% DMSO % % Tween 80 % ddH2O
计算重置

计算器

摩尔浓度计算器

摩尔浓度计算器

本计算器可帮助您计算出特定溶液中溶质的质量、溶液浓度和体积之间的关系,公式为:

质量 (mg) = 浓度 (mM) x 体积 (mL) x 分子量 (g/mol)

摩尔浓度计算公式

  • 质量
    浓度
    体积
    分子量

*在配置溶液时,请务必参考Selleck产品标签上、SDS / COA(可在Selleck的产品页面获得)批次特异的分子量使用本工具。

稀释计算器

稀释计算器

用本工具协助配置特定浓度的溶液,使用的计算公式为:

开始浓度 x 开始体积 = 最终浓度 x 最终体积

稀释公式

稀释公式一般简略地表示为: C1V1 = C2V2 ( 输入 输出 )

  • C1
    V1
    C2
    V2

在配置溶液时,请务必参考Selleck产品标签上、SDS / COA(可在Selleck的产品页面获得)批次特异的分子量使用本工具。.

连续稀释计算器方程

  • 连续稀释

  • 计算结果

  • C1=C0/X C1: LOG(C1):
    C2=C1/X C2: LOG(C2):
    C3=C2/X C3: LOG(C3):
    C4=C3/X C4: LOG(C4):
    C5=C4/X C5: LOG(C5):
    C6=C5/X C6: LOG(C6):
    C7=C6/X C7: LOG(C7):
    C8=C7/X C8: LOG(C8):
分子量计算器

分子量计算器

通过输入化合物的化学式来计算其分子量:

总分子量:g/mol

注:化学分子式大小写敏感。C10H16N2O2 c10h16n2o2

摩尔浓度计算器

质量 浓度 体积 分子量
计算

临床试验信息

NCT Number Recruitment interventions Conditions Sponsor/Collaborators Start Date Phases
NCT03310541 Active not recruiting Drug: AZD5363|Drug: Enzalutamide|Drug: Fulvestrant Breast Cancer|Prostate Cancer|Advanced Solid Tumors Memorial Sloan Kettering Cancer Center October 11 2017 Phase 1
NCT01992952 Active not recruiting Drug: AZD5363|Drug: Placebo|Drug: Fulvestrant Estrogen Receptor Positive Breast Cancer Velindre NHS Trust|AstraZeneca|Cenduit LLC|Covance|Cardiff and Vale University Health Board May 2014 Phase 1|Phase 2
NCT02338622 Completed Drug: olaparib|Drug: AZD5363 Advanced Cancer Royal Marsden NHS Foundation Trust|Institute of Cancer Research United Kingdom|AstraZeneca March 31 2014 Phase 1
NCT02121639 Active not recruiting Drug: Placebo|Drug: AZD5363 Prostate Cancer University Hospital Southampton NHS Foundation Trust|AstraZeneca|Cancer Research UK January 29 2014 Phase 1|Phase 2
NCT02077569 Completed Drug: AZD5363 Invasive Breast Cancer University of Nottingham|AstraZeneca|Cancer Research UK|National Cancer Research Network January 2014 Phase 2
NCT01692262 Completed Drug: Intermittent dosing of AZD5363 Metastatic Castrate-Resistant Prostate Cancer (mCRPC)|Efficacy|Safety and Tolerability|Pharmacokinetics|Pharmacodynamics|Tumour Response. AstraZeneca November 2012 Phase 1

技术支持

在订购、运输、储存和使用我们的产品的任何阶段,您遇到的任何问题,均可以通过拨打我们的热线电话400-668-6834,或者技术支持邮箱tech@selleck.cn,直接联系到我们。我们会在24小时内尽快联系您。

操作手册

如果有其他问题,请给我们留言。

  • * 必填项

Akt Signaling Pathway Map

Akt Inhibitors with Unique Features

相关Akt产品

Tags: 购买Capivasertib (AZD5363) | Capivasertib (AZD5363)供应商 | 采购Capivasertib (AZD5363) | Capivasertib (AZD5363)价格 | Capivasertib (AZD5363)生产 | 订购Capivasertib (AZD5363) | Capivasertib (AZD5363)代理商
×
Cell Lines Assay Type Concentration Incubation Time Formulation Activity Description PMID